Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators
Novel Activators Demonstrate Selective Inhibition of IL-17a and IL-2

Leave a Reply

Your email address will not be published.